Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen

Nuclear Medicine and Biology

Volumn 37, Issue 7, 2010, Pages 777-784

  Becker, Stéphanie ^a,b,c,d   Ardisson, Valérie ^a,b,c   Lepareur, Nicolas ^a,b,c   Sergent, Odile ^c,e   Bayat, Sahar ^f   Noiret, Nicolas ^c,g   Gaboriau, François ^b   Clément, Bruno ^b   Boucher, Evelyne ^a,b   Raoul, Jean Luc ^a,b,c   Garin, Etienne ^a,b,c  

^a CENTRE EUGÈNE MARQUIS   (France)

^b Univ Rennes   (France)

^c UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^d CENTRE HENRI BECQUEREL   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

^f PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^g UNIV RENNES   (France)

Author keywords

Dexamethasone; Fluidity; Hepatocarcinoma; Lipiodol; Tamoxifen

Indexed keywords

DEXAMETHASONE; IODINATED POPPYSEED OIL; TAMOXIFEN; TECHNETIUM 99M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL MEMBRANE FLUIDITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TUMOR LEVEL; DRUG UPTAKE; ELECTRON SPIN RESONANCE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LOW DRUG DOSE; NONHUMAN; PROCESS OPTIMIZATION; RAT; TISSUE DISTRIBUTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DEXAMETHASONE; ELECTRON SPIN RESONANCE SPECTROSCOPY; ETHIODIZED OIL; INJECTIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MEMBRANE FLUIDITY; RATS; TAMOXIFEN; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 77956985268     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.03.013     Document Type: Article

References (41)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108.
2. Bosch F.X., Ribes J., Díaz M., Cléries R. Primary liver cancer: world-wide incidence and trends. Gastroenterology 2004, 127:S5-16.
3. Bruix J., Sherman M., Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
4. 131I-Lipiodol iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997, 26:1156-1161.
5. Boucher E., Garin E., Guylligomarc'h A., Olivié D., Boudjema K., Raoul J.L. Intra-arterial injection of iodine-131-labeled Lipiodol for treatment of hepatocellular carcinoma. Radiother Oncol 2007, 82:76-82.
6. Bernal P., Raoul J.L., Stare J., Sereegotov E., Sundram F.X., Kumar A., et al. International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled Lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. Semin Nucl Med 2008, 38:S40-S45.
7. 188Re-SSS Lipiodol following injection into hepatic artery of healthy pig. Eur J Nucl Med Mol Imaging 2004, 31:542-546.
8. Salem R., Lewandowski R.J., Atassi B., Gordon S.C., Gates V.L., Barakat O., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005, 16:1627-1639.
9. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
10. Preetha A., Huilgol N., Banerjee R. Effect of fluidizing agents on paclitaxel penetration in cervical cancerous monolayer membranes. J Membrane Biol 2007, 219:83-91.
11. Auner B.G., O'Neill M.A.A., Valenta C., Hadgraft J. Interaction of phloretin and 6-ketocholestanol with DPPC-liposomes as phospholipid model membranes. Int J Pharm 2005, 294:149-155.
12. Johnston D., Melnykovych G. Effects of dexamethasone on the fluorescence polarisation of diphenylhexatriène in HeLa cells. Biochim Biophys Acta 1980, 596:320-324.
13. Boullier J.A., Melnykovych G., Barias B.G. A photobleaching recovery study of glucocorticoid effects on lateral mobilities of a lipid analog in S3G HeLa cell membranes. Biochim Biophys Acta 1982, 692:278-286.
14. Kapitulnik J., Weil E., Rabinowitz R. Glucocorticoids increase the fluidity of the fetal-rat liver microsomial membrane in the perinatal period. Biochem J 1986, 239:41-45.
15. Dudeja P.K., Foster E.S., Brasitus T.A. Modulation of rat distal colonic brush-border membrane Na+H+ exchange by dexamethasone: role of lipid fluidity. Biochim Biophys Acta 1987, 905:485-493.
16. Van Laethem F., Liang X., Andris F., Urbain J., Vandenbranden M., Ruysschaert, et al. Glucocorticoids alter the lipid and protein composition of membrane rafts of a murine T cell hybridoma. J Immunol 2003, 170:2932-2939.
17. Wiseman H., Quinn P., Halliwell B. Tamoxifen and related compounds decrease membrane fluidity in liposomes. Mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions. FEBS Lett 1993, 330:53-56.
18. Severcan F., Kazanci N., Zorlu F. Tamoxifen increases membrane fluidity at high concentrations. Biosci Reps 2000, 20:177-184.
19. Novikoff A.B. A transplantable liver tumor induced by 4-dimethylaminoazobenzene. Cancer Res 1957, 17:1010-1027.
20. Sergent O., Pereira M., Belhomme C., Chevanne M., Huc L., Lagadic-Gossmann D. Role for membrane fluidity in ethanol-induced oxidative stress of primary rat hepatocytes. J Pharmacol Exp Ther 2005, 313:104-111.
21. Ogura R., Sugiyama M., Sakanashi T., Ninomiya T. ESR spin-labeling method of determining membrane fluidity in biological materials. Kurume Med J 1988, 35:171-182.
22. Garin E., Noiret N., Malbert C.H., Lepareur N., Roucoux A., Dazord L., et al. Development of 99mTc-labeled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pig. Nucl Med Commun 2004, 25:291-298.
23. Garin E., Denizot B., Roux J., Noiret N., Lepareur N., Moreau M., et al. Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled Lipiodol in the rat. Lab Anim 2005, 39:214-220.
24. Piao Y., Shin S.C., Choi J.S. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm Drug Dispos 2008, 29:245-249.
25. Park C., Choi S.I., Kim H., Yoo H.S., Lee Y.B. Distribution of Lipiodol in hepatocellular carcinoma. Liver 1990, 10:72-78.
26. Chou F.I., Fang K.C., Chung C., Lui W.Y., Chi C.W., Liu R.S., et al. Lipiodol uptake and retention by human hepatoma cells. Nucl Med Biol 1995, 22:379-386.
27. Chou F.I., Lui W.Y., Chi C.W., Chan W.K. I-131-Lipiodol cytotoxicity in hepatoma cells. Proc Natl Sci Counc Repub China B 1994, 18:154-160.
28. Iwai K., Maeda H., Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 1984, 44:2115-2121.
29. De Baere T., Zhang X., Aubert B., Harry G., Lagrange C., Ropers J., et al. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology 1996, 201:731-735.
30. Burton M.A., Gray B.N., Coletti A. Effect of angiotensin II on blood flow in the transplanted sheep squamous cell carcinoma. Eur J Cancer Clin Oncol 1988, 24:1373-1376.
31. Sasaki Y., Imaoka S., Hasegawa Y., Nakano S., Ishikawa O., Ohigashi H., et al. Changes in distribution of hepatic blood flow induced by intraarterial infusion of angiotensin II in human hepatic cancer. Cancer 1985, 55:311-316.
32. Schuller A., Solis-Herruzo J.A., Moscat J., Fernandez-Checa J.C., Municio A.M. The fluidity of liver plasma membranes from patients with different types of liver injury. Hepatology 1986, 6:714-717.
33. Mahler S.M., Wilce P.A., Shanley B.C. Studies on regenerating liver and hepatoma plasma membranes II Membrane fluidity and enzyme activity. Int J Biochem 1988, 20:613-619.
34. Clarke R., Van den Berg H., Murphy R. Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17β-estradiol. J Natl Cancer Inst 1990, 82:1702-1705.
35. Engelke M., Bojarski P., Bloss R., Diehl H. Tamoxifen perturbs lipid bilayer order and permeability: comparison of DSC, fluorescence anisotropy, Laurdan generalized polarization and carboxyfluorescein leakage studies. Biophys Chem 2001, 90:157-173.
36. Dicko A., Morissette M., Ben Ameur S.B., Pézolet M., Di Paolo T. Effect of estradiol and tamoxifen on brain membranes: Investigation by infrared and fluorescence spectroscopy. Brain Res Bull 1999, 49:401-405.
37. Engelke M., Tykhonova S., Zorn-Kruppa M., Diehl H. Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 2002, 91:13-21.
38. Grünfeld J.P., Eloy L. Glucocorticoids modulate vascular reactivity in the rat. Hypertension 1987, 10:608-618.
39. Burton M.A., Gray B.N., Self G.W., Heggie J.C., Towensend P.S. Manipulation of experimental rat and rabbit liver tumor blood flow with angiotensin II. Cancer Res 1985, 45:5390-5393.
40. Becker S., Laffont S., Vitry F., Rolland Y., Lecloirec J., Boucher E., et al. Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled Lipiodol. Nucl Med Commun 2008, 29:815-825.
41. Rooney S.A., Gobran L., Gross I., Wai-lee T.S., Nardone L.L., Motoyama E.K. Studies on pulmonary surfactant. Effects of cortisol administration to fetal rabbits on lung phospholipid content, composition and biosynthesis. Biochim Biophys Acta 1976, 450:121-130.